American Century Companies Inc. reduced its position in shares of Cambrex Corporation (NYSE:CBM) by 90.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,948 shares of the biotechnology company’s stock after selling 116,492 shares during the period. American Century Companies Inc.’s holdings in Cambrex Corporation were worth $774,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Flinton Capital Management LLC lifted its position in shares of Cambrex Corporation by 3.8% during the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 68 shares in the last quarter. Dubuque Bank & Trust Co. lifted its position in shares of Cambrex Corporation by 3.3% during the second quarter. Dubuque Bank & Trust Co. now owns 2,697 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 87 shares in the last quarter. Louisiana State Employees Retirement System lifted its position in shares of Cambrex Corporation by 0.8% during the second quarter. Louisiana State Employees Retirement System now owns 13,300 shares of the biotechnology company’s stock valued at $795,000 after purchasing an additional 100 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Cambrex Corporation by 0.6% during the second quarter. Arizona State Retirement System now owns 16,976 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 100 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its position in Cambrex Corporation by 1.3% in the first quarter. Municipal Employees Retirement System of Michigan now owns 9,080 shares of the biotechnology company’s stock worth $500,000 after acquiring an additional 120 shares during the period. 98.28% of the stock is currently owned by institutional investors.

In other Cambrex Corporation news, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $61.39, for a total transaction of $736,680.00. Following the transaction, the chief executive officer now owns 95,328 shares in the company, valued at approximately $5,852,185.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 36,000 shares of company stock worth $2,070,960 in the last 90 days. Company insiders own 2.48% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Cambrex Corporation (CBM) Position Decreased by American Century Companies Inc.” was published by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/18/cambrex-corporation-cbm-position-decreased-by-american-century-companies-inc.html.

Shares of Cambrex Corporation (NYSE CBM) opened at 53.60 on Monday. The firm has a 50-day moving average of $53.51 and a 200 day moving average of $55.12. Cambrex Corporation has a 12 month low of $38.30 and a 12 month high of $62.95. The company has a market cap of $1.75 billion, a price-to-earnings ratio of 19.53 and a beta of 2.25.

Cambrex Corporation (NYSE:CBM) last posted its earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.76. The business had revenue of $134.55 million for the quarter, compared to analysts’ expectations of $136.82 million. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.68 EPS. On average, analysts expect that Cambrex Corporation will post $3.08 earnings per share for the current year.

Several analysts have commented on the stock. ValuEngine lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub lowered shares of Cambrex Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. Finally, Zacks Investment Research lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $64.00.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.